Similar articles for PMID: 28275504

Year	Number of Results
2009	1
2010	1
2013	1
2014	1
2015	8
2016	12
2017	11
2018	22
2019	22
2020	12
2021	6
2024	0

1

New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases.

Owen D, Otterson GA. Owen D, et al. J Thorac Dis. 2017 Feb;9(2):E158-E161. doi: 10.21037/jtd.2017.02.06. J Thorac Dis. 2017. PMID: 28275504 Free PMC article. No abstract available.

2

Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.

Naito T, Shiraishi H, Fujiwara Y. Naito T, et al. Jpn J Clin Oncol. 2021 Jan 1;51(1):37-44. doi: 10.1093/jjco/hyaa192. Jpn J Clin Oncol. 2021. PMID: 33147606 Review.

3

An autopsy case of anaplastic lymphoma kinase-positive lung cancer exacerbated in a short period of time: a case report.

Takeda M, Sato K, Sakamoto S, Suzuki M, Izumiya Y, Kumagai N, Sudo K, Okuda Y, Asano M, Sano M, Omori Y, Nakayama K. Takeda M, et al. J Med Case Rep. 2019 Apr 29;13(1):118. doi: 10.1186/s13256-019-2054-3. J Med Case Rep. 2019. PMID: 31030664 Free PMC article.

4

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. Camidge DR, et al. J Clin Oncol. 2018 Sep 10;36(26):2693-2701. doi: 10.1200/JCO.2017.77.5841. Epub 2018 May 16. J Clin Oncol. 2018. PMID: 29768119 Clinical Trial.

5

Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma.

Tao H, Cai Y, Shi L, Tang J, Liu Z, Wang Z, Bai L, Liu Z. Tao H, et al. Thorac Cancer. 2017 Jan;8(1):8-15. doi: 10.1111/1759-7714.12395. Epub 2016 Oct 24. Thorac Cancer. 2017. PMID: 27779369 Free PMC article.

6

Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.

Lin HM, Pan X, Hou P, Huang H, Wu Y, Ren K, Jahanzeb M. Lin HM, et al. J Med Econ. 2020 Aug;23(8):894-901. doi: 10.1080/13696998.2020.1762620. Epub 2020 May 21. J Med Econ. 2020. PMID: 32347754 Free article.

7

Ceritinib: A primer for pharmacists.

Au TH, Cavalieri CC, Stenehjem DD. Au TH, et al. J Oncol Pharm Pract. 2017 Dec;23(8):602-614. doi: 10.1177/1078155216672315. Epub 2016 Oct 13. J Oncol Pharm Pract. 2017. PMID: 27738095 Free article. Review.

8

Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.

Hirota T, Muraki S, Ieiri I. Hirota T, et al. Clin Pharmacokinet. 2019 Apr;58(4):403-420. doi: 10.1007/s40262-018-0689-7. Clin Pharmacokinet. 2019. PMID: 29915924 Review.

9

Control of brain metastases with alectinib in anaplastic lymphoma kinase-rearranged lung cancer.

Kwok WC, Tam TC, Lui MM, Lam DC, Ho JC. Kwok WC, et al. Respirol Case Rep. 2017 Mar 6;5(3):e00224. doi: 10.1002/rcr2.224. eCollection 2017 May. Respirol Case Rep. 2017. PMID: 28275428 Free PMC article.

10

Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.

Wang W, Sun X, Hui Z. Wang W, et al. Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17. Oncol Res Treat. 2019. PMID: 31527380 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

85 results

Results by year